Conjugates without Premature Cleavage

IntoCell

IntoCell, Into Practice

Dec. 2025

Intocell
into practice

TABLE OF CONTENTS



Introduction

Intocell
into practice

01 Introducing IntoCell

- Founded in 2015; **KOSDAQ**-listed (May 2025)
- **46 employees** including **21 medicinal chemists** and **14 biologists**
- Developed **two Platform Technologies**, **Focused Libraries of Payload**, and Pipelines of novel ADCs

OHPAS™ Linker	**PMT™ Technology**	**Payload Libraries**	**ADC Pipeline**
A novel self-immolative group (SIG) with highly flexible cleavage chemistry dubbed as OHPAS	A Payload Modification Technology to improve therapeutic index	• Benzodiazepine: 2 patents • Duocarmycin: 2 patents • Nexatecan: 1 patent • iso-Nexatecan: 1 patent • PNU: 1 patent	Pre-clinical + Clinical; The most advanced is a ITC-6146RO (B7-H3 ADC), **IND cleared by both FDA & MFDS for Ph1**

- Our core assets are protected by multiple **patents filed** in Korea, US, and through the PCT, as supported by **robust synthetic routes that enable production** at multi-gram scale

02 Company Overview

설립일	2015. 04. 01	소재지	대전시 대덕구 신일동로 101
자본금	75억원 (14,997,600주)	임직원	총 46명 (임원 8 / 직원 38)
최대주주	박태교 대표이사 등* 25.62%	액면가	500원

* 최대주주 및 특수관계인 8인과 특별관계인 6인 합산 (스톡옵션 등 감안 시 25.69%)
SI(리가켐바이오, 상장 후 3년 확약) 2.93% 포함 시 우호지분 28.56%

연구개발 / BD 인력

- 박사 8 / 석사 32
- LG, 리가켐바이오 근무
- Amgen 등 글로벌 제약사

풍부한 경험과 역량

- 합성신약 → 기술수출
- ADC → 기술수출
- 벤처창업 → 코스닥 상장



핵심기술 / Pipeline

- OHPAS™ Linker
- PMT™ Technology
- Payload Libraries
  - Benzodiazepines
  - Duocarmycins
  - Nexatecan™ & iso-Nexatecan™
  - PNU
- B7-H3 ADC
  & 5T4, DLL3, PSMA, HER3 ADC

03 Founders and Leadership: CEO

박태교 대표이사

서울대학교 화학과 (1983년)

서울대학교 화학과 석사 (1985년)

MIT 화학과 박사 (1992년)

Yale Univ. Post-Doc (1992 ~ 1993년)

Memorial Sloan-Kettering Cancer Center, Post-Doc (1993 ~ 1995년)

LG 생명과학 기술연구원 (1995 ~ 2006년)

㈜리가켐바이오사이언스 (2006 ~ 2015년)

- 공동창업 / 코스닥 상장주역
- CTO (수석부사장)

현 인투셀 대표 (2015 ~)

연구논문 31편, 국제특허 > 30건

연구경력 40년 이상

03 Founders and Leadership: CEO

연구 기관	대표 연구 업적	Comment
박사 과정	Self-Replicating Molecule 연구 Science 지 게재	Nature 해설기사, C&EN 보도 (논문 5편)
박사 후 과정	Globo-H 합성	C&EN 보도 (논문 13편)
LG 생명과학	항응혈제 연구	LG 그룹 연구 대상 (2004) 기술연구원 창의상 (2005) 수상
LigaChem Bio	ConjuALL™ 발명 Cyclic Amidrazone 발명	수 건의 L/O 토대 Nokxaban (항응혈제, GC녹십자 공동개발) 및 Delpazolid (항생제, 리가켐 개발 중)에 활용
IntoCell	**OHPAS™ 발명** PMT Approach 창안	현존 최고의 Linker Technology B7-H3 개발 후보 기적용, 타 PJT 활용

가장 파급력 있는 연구결과 “OHPAS Technology”

05 IntoCell is Evolving

누적조달금액: 851억원

국책선정금액: 76억원



* 특허는 우선일 적용받는 가출원일자 기준

Intocell into practice

IntoCell Technology

01. OHPAS™ Linker
02. PMT™ Technology
03. Payload Libraries
04. Pipelines

Intocell
into practice

01 Ortho Hydroxy-Protected Aryl Sulfate (OHPAS) Linker



Main feature:

- Generality
- Stability
- Compatibility

Basic structure

Bioconjugate Chem. **2019**, *30*, 1957−1968.

Phenolic spacer introduced

Bioconjugate Chem. **2019**, *30*, 1969−1978.

01 OHPAS ADCs: Proven Efficacy Across Diverse Payloads (Generality)

Various OHPAS ADCs → Highly efficacious when tested in vivo













Intocell into practice

01 OHPAS Linker is Compatible with Many Toxins Used in ADC Field

All compounds tested as Trastuzumab* conjugates (In Vitro Activity, HER2 ADC)

IC_{50} (nM) >>		T-DM1	ITC-501	ITC-502	ITC-507	ITC-508	ITC-509	ITC-510	ITC-520	ITC-516
DAR >>		3.5	2.0	1.7	1.9	2.0	2.0	2.0	2.0	1.8
Toxin	***ABS**	**DM1**	**MMAF**	**Amanitin**	**dPBD**	**CBI indole**	**dCBI**	**Auristatin F**	**dTBD**	**Phenpan**
SK-Br-3(3+)	5,514,307	0.035	0.017	0.026				0.010		0.898
		*0.036		0.600	0.015	0.029	0.010		0.007	
NCI-N87(3+)	2,826,736	0.258	0.203					0.163		4.757
		*0.218		0.115	0.028	0.083	0.025		0.015	
SK-OV3(3+)	4,320,935	0.140	0.310	0.149				0.262		>500
		*0.106			0.045	0.041	0.020		ND	
JIMT-1(2+)	363,570	1.758	0.172	>50				0.092		250
		*2.815			0.075	0.029	0.019		0.056	
MCF7(-)	42,167	>50	>50	>50				ND		ND
		*>40			>50	0.584	ND		ND	
MDA-MB-468(-)	144	8.920	>50	>50				>50		ND
		*9.940			3.781	0.176	3.001		ND	

T-DM1: purchased
Trastuzumab* = A121C variant of Trastuzumab @HC
DAR is estimated from HPLC peak area after isolation

ND: Not determined
MTT assay: 4 day
*MTT assay: 6 day
*ABS: antibody binding site

Intocell into practice

01 OHPAS Linker Proved to be Highly Stable in Plasma (Stability)

Superior Blood Stability Across Species (vs. VC-PABC Conjugate)

Plasma Stability Assessment Data by Species

Mouse Rat Monkey Human

Intocell into practice

OHPAS™ Applied

B7-H3 MMAF ADC
(ITC-6103RO)







Seagen

VC-PABC Applied

B7-H3 MMAF ADC
(ITC-6104RO)







01 OHPAS Mitigates Bone Marrow Toxicity

ADC		Neutropenia	Thrombocytopenia	Anemia	ILD‡
		> Grade 3 (any grade)			
MGC-018, PI/II, FIH Study		**22.1%**	7%	5.8%	
Adcetris, Phase III		**29%**		4%	
Enhertu	Phase III	**19.1%**	7%	5.8%	
	Destiny-Gastric01	**51%** (72%), (**4.8****%)			2.4% (10%)

* Treatment Emergent Adverse Effect
‡ Interstitial Lung Disease
** Febrile neutropenia of any grade

- **OHPAS Conjugates Are Expected to Cause Reduced Neutropenia**

OHPAS linkers are resistant to enzymes of any kind:
Payloads are released only by designated enzymes in lysosomes

ADCs with Peptide linker



or other Peptide Linker

VS

ADCs with OHPAS Linker



02 Payload Modification Technology (PMT): To Increase Therapeutic Index → Non-Specific Uptake ↓

PMT reduces non-selective uptake of ADC through inhibition of drug-membrane interaction



02 Modifying Group(MG) Reduces Non-specific Uptake of ADC by Negative Cells



Polarity of MG:
MG-1 < MG-2 < MG-3

- MG significantly increases selectivity for B7-H3 positive over negative cells
- MG group reduces normal cell uptake, resulting in improved PK in vivo
- PMT helps enhance TI of ADC

ADC (DAR 2)	MG	in vitro MTT IC_{50} (nM)	
		JIMT-1(++)	CCRF-CEM(-)
ITC-6122RO	none	0.20±0.09	5.84±0.52
ITC-6121RO	MG-1	0.44±0.31	34.2±0.8
ITC-6145RO	MG-2	0.32±0.22	989±50
ITC-6146RO	**MG-3**	**0.30±0.13**	**1006±29**

Polarity ↑

Selectivity 172-fold ↑ by PMT

In vivo

JIMT-1 Xenograft Study



Intocell into practice

03 OHPAS-able & TBA-able Libraries of Payloads

Nexatecans & iso-Nexatecans



SN-38

OHPAS-compatible Camptothecins



Camptothecin with Phenol Function

Nexatecan (NxT)

(+ GGFG-compatible)

TBA-compatible Camptothecins



Camptothecin with Alcohol Function

iso-Nexatecan (iNxT)

Other OHPAS-able Payload Libraries

OHPAS-able dPBD	OHPAS-able Duocarmycin	OHPAS-able Doxorubicinoid
• Symmetrical & Unsymmetrical • Patent (US Application No.) 1) 16/425,237 2) 17/289,545	• PMT-applied Duocarmycin • Applied to in-house PGM (ITC-6146RO) • Patent (US Application No.) 1) 18/084,739 2) 17/358,306	• PNU-derivatives • Patent (KR Application No.) 1) 10-2025-0101218

03 Nexatecans & their ADCs are Highly Potent

	Code number	DAR	Compds	IC_{50} (nM, n≥3)					
				Cell	**SK-BR-3 (Breast)**	NCI-N87 (Gastric)	JIMT-1 (Breast)	HCT116 (Colon)	**MDA-MB-468 (TNBC)**
				Her2 (×10⁵)	**16.7**	**13.3**	**1.7**	**0.2**	**0.003**
Drug	ITC02-036	-	SN38		1.12	6.52	40.8	10.5	0.675
	ITC02-108	-	DXd		1.32	3.80	35.3	11.4	0.450
	ITC02-127	**-**	**Nexatecan3 (NxT3)**		**0.31**	**0.45**	N/D	N/D	**0.168**
ADC	ITC-5140	7.4	HER2-OHPAS-SN38		0.470	2.18	1650	522	40.2
	Enhertu	7.7	HER2-GGFG-DXd		0.115	0.370	496	570	56.3
	ITC-5148a	**7.5**	**HER2-OHPAS-NxT3**		**0.074**	**0.175**	N/D	N/D	**26.4**
	T-DM1	3.5	HER2- MCC-DM1		0.143	0.072	2.24	35.3	23.2



ITC02-036 (SN38)



ITC02-108 (DXd)



OHPAS-NxTs

- A series of NxTs and their trastuzumab ADCs were tested
- Anti-HER2-NxT3 showed the highest potency
- Conjugation via maleimide or bromoacetamide routinely yielded DAR 8 without aggregation

03 HER2 NxT3 ADC (ITC-5148a) Is Safer Than Enhertu® in Cyno Studies

Parameters	Major Findings	
	ITC-5148a (30, 50, 75 mg/kg, Q3Wx3) 1M/1F (Main)	Enhertu (10, 30, 78.8 mg/kg, Q3Wx3)* 3M/3F (Main) + 2M/2F (Recovery)
Mortality	**No mortality occurred up to 75 mpk**	**One moribund female was found at 78.8 mpk (Day 26)**
Body Weight	75 mg/kg (M) : decrease body weight	78.8 mg/kg: decreased body weight
Food Consumption	No test article-related significant changes	78.8 mg/kg: decreased food consumption
Clinical observation	No test article-related significant changes	78.8 mg/kg: diarrhea, abnormal skin color (blackish brown)
Hematology	75 mg/kg : decreased red blood cells, increased reticulocyte and platelets	≥ 30 mg/kg: decreased red blood cell parameters (erythrocytes, hemoglobin, hematocrit)
Clinical Chemistry	No test article-related significant changes	≥10 mg/kg: increases in AST, LDH, and CK
Gross Pathology	50, 75 mg/kg : No test article-related significant changes	78.8 mg/kg: black foci in the skin, white foci in the lungs
Histopathology	**No test article-related significant changes**	**30, 78.8 mg/kg : Skin pigmentation and lung lesions were not recovered after 6-week recovery periods**
HNSTD	**> 75 mg/kg**	**30 mg/kg**

* Enhertu data from NDA

03 PEGylated ADC Outperforms non-PEGylated in vivo









Intocell into practice

03 New Sets of Nexatecans

Re-evaluation of existing / newly discovered NxTs

- Equal or better than existing NxTs

IC_{50} (nM)

약물	SK-BR-3*		NCI-N87*		MDA-MB-468*	
	Free	ADC**	Free	ADC**	Free	ADC**
NxTA	0.68	0.06	2.97	0.25	0.50	153.6
NxTX	0.28	0.06	0.32	0.08	0.14	5.54
NxTY	0.32	0.06	1.04	0.20	0.21	44.9
NxTZ	0.36	0.08	1.06	0.21	0.20	5.05
NxT3	0.31	0.07	0.48	0.13	0.18	30.0
Exatecan	0.53	0.39	0.75	1.65	0.32	3.59
DXd	1.28	0.11	4.79	0.36	0.44	56.0

* Average of ≥ 3 tests
** HER2 ADC

03 Re-evaluation Confirms NxT A, X, Y & Z are Promising

Drugs & ADCs are Compared with DXd against HER2 target

In Vitro Activity

Drug	Linker-Drug	DAR	IC_{50} ± SD (nM) SK-BR-3 (Breast) HER2 ($x10^5$) 21.8	NCI-N87 (Gastric) HER2 ($x10^5$) 13.2	MDA-MB-468 (TNBC) HER2 ($x10^5$) 0.003
Drug	DXd	-	1.28 ±0.18	4.79 ±1.32	0.44 ±0.10
	NxT3	-	0.31 ±0.03	0.48 ±0.16	0.18 ±0.03
	NxTA	-	0.77 ±0.05	3.60 ±1.02	0.58 ±0.22
	NxTX	-	0.28 ±0.04	0.32 ±0.03	0.14 ±0.03
	NxTY	-	0.32 ±0.04	1.04 ±0.11	0.21 ±0.28
	NxTZ	-	0.36 ±0.03	1.06 ±0.03	0.20 ±0.01
ADC	GGFG-DXd (Enhertu)	7.7	0.11 ±0.05	0.36 ±0.12	56.0 ±15.4
	OHPAS-NxT3	7.5	0.07 ±0.02	0.15 ±0.09	28.2 ±8.40
	OHPAS-NxTA	7.8	0.06 ±0.00	0.25 ±0.04	111.9 ±10.2
	OHPAS-NxTX	8.0	0.06 ±0.00	0.08 ±0.02	5.54 ±0.73
	OHPAS-NxTY	7.4	0.06 ±0.01	0.20 ±0.05	44.9 ±5.49
	OHPAS-NxTZ	7.4	0.08 ±0.03	0.21 ±0.08	44.9 ±5.49

In Vivo Efficacy



Linker-Drug	TGI (%), Day42	Rank
GGFG-DXd	23	4
OHPAS-NxTA	36	2
OHPAS-NxT3	26	3
OHPAS-NxTY	44	1

Application of PMT principle in progress

03 Iso-Nextecan Looks Even Better

In Vivo Efficacy of 5T4 ADCs

[MDA-MB-468, TNBC Model, 3 mpk, single IV]



[NCI-H23, NSCLC Model, single IV]
10 mpk (DXd, NxT3, iNxT1), 5 mpk (mDUBA)



Linker-Drug	DAR	IC_{50} ± SD (nM)			
		MDA-MB-468, TNBC	NCI-H23, NSCLC	MDA-MB-468 /NCI-H23	NCI-N87 (-), Stomach
GGFG-DXd	7.5	0.08 ±0.04	34.7 ±6.85	1431 / 5	115 ±10.4
OHPAS(PM)-NxT3	7.8	0.20 ±0.08	0.84 ±0.64	207 / 8	37.9 ±16.2
GGFG-iNxT1	7.9	0.07 ±0.01	22.4 ±4.85	868 / 3	61.3 ±17.9
BS-OHPAS-mDUBA	3.9	0.002 ±0.000	0.44 ±0.11	6895 / 36	16.0 ±0.21
IAA-OHPAS-mDUBA	3.7	0.006 ±0.002	4.03 ±2.57	6262 / 16	62.6 ±6.30

03 NxTs & iNxTs Work Well with Other Targets as Well

In Vivo Efficacy of DLL3 ADCs

[SHP-77, SCLC Model, 1 mpk, single IV]



Linker-Drug	DAR	IC_{50} ± SD (nM)	TGI(%), DAY21	Rank
GGFG-DXd	8	4.61 ± 0.99	56	6
OHPAS(PMT)-NxT3	8	0.06 ± 0.05	82	5
GGFG-iNxT1	8	0.002 ± 0.00	102	2
OHPAS-NxTX	8	0.003 ± 0.00	95	4
OHPAS-NxTY	8	0.02 ± 0.03	93	3
OHPAS-mDUBA-PMT	4	0.001 ± 0.00	105	1

In Vivo Efficacy of PSMA ADCs

[C4-2, Prostate Model, 5 mpk, single IV]



Linker-Drug	DAR	IC_{50} ± SD (nM)	TGI(%), DAY21	Rank
OHPAS(PMT)-NxT3	8	0.24±0.07	101	1
GGFG-DXd	8	3.42±1.54	76	3
GGFG-iNxT1	8	0.14±0.02	98	2

04 Pipeline Overview

IntoCell Pipeline

Target		ADC Lead Optimization	ADC Lead Validation	Preclinical Development	Clinical Development
B7-H3 ADC	Solid Cancers				IND Approved (MFDS, 2025) IND Cleared (FDA, 2025)
5T4 ADC	Solid Cancers				
DLL3 ADC	Solid Cancers				
HER3 ADC	Solid Cancers		KDDF funded PJT * (ongoing)		
PSMA ADC	Solid Cancers				

Collaboration Pipeline

Target		ADC Lead Optimization	ADC Lead Validation	Preclinical Development	Clinical Development
Undisclosed	Solid Cancers	Undisclosed			
Undisclosed	Solid Cancers				
Undisclosed	Solid Cancers				

04 ITC-6146RO: anti-B7-H3 ADC

ITC-6146RO (ADC)



B7-H3 mAb + OHPAS™ + PMT™

- Promising B7-H3 ADC with broad applicability across solid tumors, particularly in lung, breast, and prostate cancer indications

in vivo efficacy in CDX model [1)]

Cell line	Cancer Types	Day	TGI
Calu-6	Lung	24	107.24%
JIMT-1	Breast	46	107.88%
PC-3	Prostate	14	109.23%

(+ 2 PDX models)

Result of NHP



- No neutropenia observed, unlike other ADCs

Expectation Best-in-class safety and stability profile supports strong commercial potential versus competing ADCs

Plan



- IND approved (MFDS): Dec. 2025
- IND Cleared (FDA): Nov. 2025

1) ITC-6146RO single-dosing per cell line: 3 mg/kg (Calu-6), 4 mg/kg (JIMT-1, PC-3)

IntoCell IP Strategy

01. 인투셀 특허 현황 및 전략
02. 다양한 특허군으로 특허 방어
03. 특허 ISR 보고서에 대한 대응

Intocell
into practice

01 인투셀 특허 현황 및 전략

차별화된 특허 전략

① **선 USP 출원 후 PCT 진입 전략**
- 미국 가출원제도 장점 적극 활용

② **중요도에 따른 출원국 숫자 조정**
- 핵심특허: US 포함 15여 개국
- 비핵심특허: US, CN, JP, India 등 5~6개국

③ **전문가 위주의 IP 팀**
- 특허 담당 임원 1명
- 특허사무소 경력 팀장, 실무 경력 팀원 구성

④ **특허 포트폴리오 구성에 과감한 투자**
- 연간 6~8억원 특허비용 소요 (최근 >10억원)



특허 현황

- 원특허 12개 / 개별국 기준 총 100개
- 등록 특허 32개 (등록 결정된 특허 포함 시 35건)

[2025년 9월 기준]

No.	기술 구분	출원번호	출원/등록 현황
1	OHPAS Linker	16/628,482	출원: 15개국 / 등록: US 등 8개
2	extended OHPAS (1)	17/419,030	출원: 12개국 / 등록: JP 등 2개
3	extended OHPAS (2)	17/419,435	출원: 7개국 / 등록: JP 등 2개
4	BGal SIG	16/472,983	출원: 5개국 / 등록: US 등 5개
5	BD 약물 (1)	16/425,237	출원: 13개국 / 등록: US 등 8개
6	BD 약물 (2)	17/289,545	출원: 13개국 / 등록: EU 등 6개
7	AgDC (PMT)	18/084,739	출원: 6개국 / 등록 심사중
8	AMA	17/781,467	출원: 3개국 / 등록 심사중
9	B7-H3 ADC (PMT)	17/358,306	출원: 13개국 / 등록: US 1개
10	Nexatecan	19/002,904	US 출원 및 PCT 출원 (개국 진입 예정)
11	iso-Nexatecan	63/836,941	US 가출원
12	PNU	10-2025-0101218	KR 가출원

* 출원번호는 US 특허 기준 (PNU 제외)

02 다양한 특허군으로 특허 방어

OHPAS-Nexatecan ADC의 특허 방어전략 예





(+ 공정특허, + formulation 특허, etc.)

Intocell
into practice

03 특허 ISR 보고서에 대한 대응

ISR (International Search Report)

- PCT 국제출원 이후, 지정된 국제조사기관(ISA, International Searching Authority)이 작성하는 보고서
- 출원된 발명의 특허성(신규성, 진보성 등)을 조기에 평가하여 출원인이 개국 진입 등 후속 절차를 준비하는데 도움주기 위한 것

Nexatecan 특허 관련 ISR의 제시 문헌과 대응방안

A: prior art - 유사 또는 동일 기술 공개 의미
X: prior art, but not patentable - 신규성, 진보성 부정할 정도는 아니나 유사 기술 존재 의미
Y: prior art and negates patentability - 특허 받을 정도의 차별성을 갖지 못한다는 의미

kr20230149767a_p	us20130012467a1p	Wowo17_120190a1p
		5,6-dihydro-4H-benzo[de] quinoline camptothecin (BQC 물질 구조 제시)
X, Y, A	X	X

- 넥사테칸 특허 구조 중 하나에서 중간체로 사용되는 물질
- 물질 자체로의 개발은 의미가 없는 중간체임
- 향후 개별국 진입 시 권리범위 재설정 계획

- 넥사테칸 특허에 포함된 구조 중 하나와 동일 구조 기재되어 있음
- 그러나, BQC 물질은 특허 만료되어 자유실시 가능한 기술임
- OHPAS 링커 도입을 통해 효능데이터 기반으로 특허화 가능

IntoCell Vision

Intocell
into practice

01 IntoCell Vision

Global Bio-Technology Giant

"2030+, into 10-10"

(인투셀 기술을 적용하여 개발한 신약 10개, 시가총액 10조 원 목표)



OHPAS™ 약물 링커 플랫폼 기술 기반, ADC 시장의

" True Game Changer "

Intocell

into practice

Thank You